nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

23.09.2023 | Research

Identification of glycogene-based prognostic signature and validation of B3GNT7 as a potential biomarker and therapeutic target in breast cancer

verfasst von: Xin Wang, Yida Wang, Xuanming Chen, Yufei He, Xunyu Zhou, Sitong Jiao, Zilin Zhu, Chuanfang Wu, Jinku Bao

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 19/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

Breast cancer is the most common cancer worldwide, with the fifth highest mortality rate among all cancers and high risk of metastasis. However, potential biomarkers and molecular mechanisms underlying the stratification of breast cancer in terms of clinical outcomes remain to be investigated. Therefore, we aimed to find a novel prognostic biomarker and therapeutic target for breast cancer patients.

Methods

Unsupervised hierarchical clustering was used to perform comprehensive transcriptomic study of total 185 glycogenes in public datasets of breast cancer with clinicopathological and survival information. A glycogene-based signature for subtype classification was discovered using Limma packages, and relevance to four known molecular features was identified by GSVA. Experimental verification was performed and biological functions of B3GNT7 were characterized by quantitative RT-PCR, western blot, transwell assays, and lectin immunofluorescence staining in breast cancer cells.

Results

A 23-glycogene signature was identified for the classification of breast cancer. Among the 23 glycogenes, B3GNTs showed significantly positive associations with ER⁻/Her2⁻ subtype in breast cancer patients (n = 2655). Overexpressed B3GNT7 were correlated with poor prognosis in breast cancer patients based on public datasets. B3GNT7 depletion inhibited cell proliferation, migration, and invasion, and decreased global fucosylation in MDA-MB-231 and HCC1937 breast cancer cells.

Conclusions

Herein, we discovered a unique 23-gene signature for breast cancer patient glycogene-type classification. Among these genes, B3GNT7 was shown to be a potential biomarker for unfavorable outcomes and therapeutic target of breast cancer.

Nur mit Berechtigung zugänglich

Abd Hamid UM, Royle L, Saldova R et al (2008) A strategy to reveal potential glycan markers from serum glycoproteins associated with breast cancer progression. Glycobiology 18(12):1105–1118. https://doi.org/10.1093/glycob/cwn095CrossRefPubMed

Biskup K, Braicu EI, Sehouli J et al (2013) Serum glycome profiling: a biomarker for diagnosis of ovarian cancer. J Proteome Res 12(9):4056–4063. https://doi.org/10.1021/pr400405xCrossRefPubMed

Carroll DJ, Burns MWN, Mottram L et al (2022) Interleukin-22 regulates B3GNT7 expression to induce fucosylation of glycoproteins in intestinal epithelial cells. J Biol Chem 298(2):101463. https://doi.org/10.1016/j.jbc.2021.101463CrossRefPubMed

Cerami E, Gao J, Dogrusoz U et al (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2(5):401–404. https://doi.org/10.1158/2159-8290.CD-12-0095CrossRefPubMed

Cohen EN, Fouad TM, Lee BN et al (2019) Elevated serum levels of sialyl Lewis X (sLe(X)) and inflammatory mediators in patients with breast cancer. Breast Cancer Res Treat 176(3):545–556. https://doi.org/10.1007/s10549-019-05258-0CrossRefPubMedPubMedCentral

Dalangood S, Zhu Z, Ma Z et al (2020) Identification of glycogene-type and validation of ST3GAL6 as a biomarker predicts clinical outcome and cancer cell invasion in urinary bladder cancer. Theranostics 10(22):10078–10091. https://doi.org/10.7150/thno.48711CrossRefPubMedPubMedCentral

Engle DD, Tiriac H, Rivera KD et al (2019) The glycan CA19-9 promotes pancreatitis and pancreatic cancer in mice. Science 364(6446):1156–1162. https://doi.org/10.1126/science.aaw3145CrossRefPubMedPubMedCentral

Fackenthal JD, Olopade OI (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer 7(12):937–948. https://doi.org/10.1038/nrc2054CrossRefPubMed

Ferlay J, Colombet M, Soerjomataram I et al (2021) Cancer statistics for the year 2020: an overview. Int J Cancer. https://doi.org/10.1002/ijc.33588CrossRefPubMed

Fernandez-Martinez A, Pascual T, Singh B et al (2023) Prognostic and predictive value of immune-related gene expression signatures vs tumor-infiltrating lymphocytes in early-stage ERBB2/HER2-positive breast cancer: a correlative analysis of the CALGB 40601 and PAMELA trials. JAMA Oncol 9(4):490–499. https://doi.org/10.1001/jamaoncol.2022.6288CrossRefPubMedPubMedCentral

Gao J, Aksoy BA, Dogrusoz U et al (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6(269):pl1. https://doi.org/10.1126/scisignal.2004088CrossRefPubMedPubMedCentral

Gao S, Wu X, Lou X, Cui W (2022) Identification of a prognostic risk-scoring model and risk signatures based on glycosylation-associated cluster in breast cancer. Front Genet 13:960567. https://doi.org/10.3389/fgene.2022.960567CrossRefPubMedPubMedCentral

Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22(8):1736–1747. https://doi.org/10.1093/annonc/mdr304CrossRefPubMedPubMedCentral

Gomes C, Almeida A, Barreira A et al (2019) Carcinoembryonic antigen carrying SLe(X) as a new biomarker of more aggressive gastric carcinomas. Theranostics 9(24):7431–7446. https://doi.org/10.7150/thno.33858CrossRefPubMedPubMedCentral

Gong Y, Ji P, Yang YS et al (2021) Metabolic-pathway-based subtyping of triple-negative breast cancer reveals potential therapeutic targets. Cell Metab 33(1):51-64 e59. https://doi.org/10.1016/j.cmet.2020.10.012CrossRefPubMed

Hanzelmann S, Castelo R, Guinney J (2013) GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinform 14:7. https://doi.org/10.1186/1471-2105-14-7CrossRef

Harbeck N, Gnant M (2017) Breast cancer. Lancet 389(10074):1134–1150. https://doi.org/10.1016/S0140-6736(16)31891-8CrossRefPubMed

Harbeck N, Penault-Llorca F, Cortes J et al (2019) Breast Cancer. Nat Rev Dis Prim 5(1):66. https://doi.org/10.1038/s41572-019-0111-2CrossRefPubMed

Huang Y, Zhang HL, Li ZL et al (2021) FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer. Nat Commun 12(1):2672. https://doi.org/10.1038/s41467-021-22618-xCrossRefPubMedPubMedCentral

Jeschke U, Mylonas I, Shabani N et al (2005) Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis. Anticancer Res 25(3A):1615–1622PubMed

Jezequel P, Campone M, Gouraud W et al (2012) bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer. Breast Cancer Res Treat 131(3):765–775. https://doi.org/10.1007/s10549-011-1457-7CrossRefPubMed

Jiang YZ, Ma D, Suo C et al (2019) Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies. Cancer Cell 35(3):428-440 e425. https://doi.org/10.1016/j.ccell.2019.02.001CrossRefPubMed

Kitayama K, Hayashida Y, Nishida K, Akama TO (2007) Enzymes responsible for synthesis of corneal keratan sulfate glycosaminoglycans. J Biol Chem 282(41):30085–30096. https://doi.org/10.1074/jbc.M703695200CrossRefPubMed

Kong K, Zhao Y, Xia L, Jiang H, Xu M, Zheng J (2021) B3GNT3: a prognostic biomarker associated with immune cell infiltration in pancreatic adenocarcinoma. Oncol Lett 21(2):159. https://doi.org/10.3892/ol.2020.12420CrossRefPubMed

Lanczky A, Gyorffy B (2021) Web-based survival analysis tool tailored for medical research (KMplot): development and implementation. J Med Internet Res 23(7):e27633. https://doi.org/10.2196/27633CrossRefPubMedPubMedCentral

Li CW, Lim SO, Chung EM et al (2018) Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell 33(2):187-201 e110. https://doi.org/10.1016/j.ccell.2018.01.009CrossRefPubMedPubMedCentral

Lin S, Tan Z, Cui H et al (2022) Identification of glycogene signature as a tool to predict the clinical outcome and immunotherapy response in breast cancer. Front Oncol 12:854284. https://doi.org/10.3389/fonc.2022.854284CrossRefPubMedPubMedCentral

Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G (2021) Breast cancer. Lancet 397(10286):1750–1769. https://doi.org/10.1016/S0140-6736(20)32381-3CrossRefPubMed

Lombard V, GolacondaRamulu H, Drula E, Coutinho PM, Henrissat B (2014) The carbohydrate-active enzymes database (CAZy) in 2013. Nucl Acids Res 42(Database issue):D490-495. https://doi.org/10.1093/nar/gkt1178CrossRefPubMed

Lu CH, Wu WY, Lai YJ, Yang CM, Yu LC (2014) Suppression of B3GNT7 gene expression in colon adenocarcinoma and its potential effect in the metastasis of colon cancer cells. Glycobiology 24(4):359–367. https://doi.org/10.1093/glycob/cwu002CrossRefPubMed

Luna A, Rabassa ME, Isla Larrain M et al (2020) Breast cancer cutaneous metastases are associated to uMUC1 and sialyl Lewis x and to highly malignant primary tumors. Pathol Res Pract 216(4):152859. https://doi.org/10.1016/j.prp.2020.152859CrossRefPubMed

Miao Z, Cao Q, Liao R et al (2022) Elevated transcription and glycosylation of B3GNT5 promotes breast cancer aggressiveness. J Exp Clin Cancer Res 41(1):169. https://doi.org/10.1186/s13046-022-02375-5CrossRefPubMedPubMedCentral

Miller KD, Nogueira L, Mariotto AB et al (2019) Cancer treatment and survivorship statistics. CA Cancer J Clin 69(5):363–385. https://doi.org/10.3322/caac.21565CrossRefPubMed

Moremen KW, Ramiah A, Stuart M et al (2018) Expression system for structural and functional studies of human glycosylation enzymes. Nat Chem Biol 14(2):156–162. https://doi.org/10.1038/nchembio.2539CrossRefPubMed

Narimatsu H (2004) Construction of a human glycogene library and comprehensive functional analysis. Glycoconj J 21(1–2):17–24. https://doi.org/10.1023/B:GLYC.0000043742.99482.01CrossRefPubMed

Narimatsu Y, Joshi HJ, Nason R et al (2019) An atlas of human glycosylation pathways enables display of the human glycome by gene engineered cells. Mol Cell 75(2):394-407 e395. https://doi.org/10.1016/j.molcel.2019.05.017CrossRefPubMedPubMedCentral

Paik S, Shak S, Tang G et al (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351(27):2817–2826. https://doi.org/10.1056/NEJMoa041588CrossRefPubMed

Parker JS, Mullins M, Cheang MC et al (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27(8):1160–1167. https://doi.org/10.1200/JCO.2008.18.1370CrossRefPubMedPubMedCentral

Petit D, Teppa RE, Harduin-Lepers A (2021) A phylogenetic view and functional annotation of the animal beta1,3-glycosyltransferases of the GT31 CAZy family. Glycobiology 31(3):243–259. https://doi.org/10.1093/glycob/cwaa086CrossRefPubMed

Rademacher TW, Parekh RB, Dwek RA (1988) Glycobiology. Annu Rev Biochem 57:785–838. https://doi.org/10.1146/annurev.bi.57.070188.004033CrossRefPubMed

Schroth W, Buttner FA, Kandabarau S et al (2020) Gene expression signatures of BRCAness and tumor inflammation define subgroups of early-stage hormone receptor-positive breast cancer patients. Clin Cancer Res 26(24):6523–6534. https://doi.org/10.1158/1078-0432.CCR-20-1923CrossRefPubMed

Scott DA, Casadonte R, Cardinali B et al (2019) Increases in tumor N-glycan polylactosamines associated with advanced HER2-positive and triple-negative breast cancer tissues. Proteomics Clin Appl 13(1):e1800014. https://doi.org/10.1002/prca.201800014

Stowell SR, Ju T, Cummings RD (2015) Protein glycosylation in cancer. Annu Rev Pathol 10:473–510. https://doi.org/10.1146/annurev-pathol-012414-040438CrossRefPubMedPubMedCentral

Vajaria BN, Patel PS (2017) Glycosylation: a hallmark of cancer? Glycoconj J 34(2):147–156. https://doi.org/10.1007/s10719-016-9755-2CrossRefPubMed

van’t Veer LJ, Dai H, van de Vijver MJ et al (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415(6871):530–536https://doi.org/10.1038/415530a

Wu Y, Luo J, Li H, Huang Y, Zhu Y, Chen Q (2022) B3GNT3 as a prognostic biomarker and correlation with immune cell infiltration in lung adenocarcinoma. Ann Transl Med 10(6):295. https://doi.org/10.21037/atm-22-493CrossRefPubMedPubMedCentral

Xiao Y, Ma D, Zhao S et al (2019) Multi-omics profiling reveals distinct microenvironment characterization and suggests immune escape mechanisms of triple-negative breast cancer. Clin Cancer Res 25(16):5002–5014. https://doi.org/10.1158/1078-0432.CCR-18-3524CrossRefPubMed

Yang Y, Vankayalapati H, Tang M et al (2020) Discovery of novel inhibitors targeting multi-UDP-hexose pyrophosphorylases as anticancer agents. Molecules. https://doi.org/10.3390/molecules25030645CrossRefPubMedPubMedCentral

Yin L, Duan JJ, Bian XW, Yu SC (2020) Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res 22(1):61. https://doi.org/10.1186/s13058-020-01296-5CrossRefPubMedPubMedCentral

Yoneyama T, Ohyama C, Hatakeyama S et al (2014) Measurement of aberrant glycosylation of prostate specific antigen can improve specificity in early detection of prostate cancer. Biochem Biophys Res Commun 448(4):390–396. https://doi.org/10.1016/j.bbrc.2014.04.107CrossRefPubMed

Titel: Identification of glycogene-based prognostic signature and validation of B3GNT7 as a potential biomarker and therapeutic target in breast cancer
verfasst von: Xin Wang
Yida Wang
Xuanming Chen
Yufei He
Xunyu Zhou
Sitong Jiao
Zilin Zhu
Chuanfang Wu
Jinku Bao
Publikationsdatum: 23.09.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 19/2023
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-023-05345-2

Enhancing prognostic accuracy: a SEER-based analysis for overall and cancer-specific survival prediction in cervical adenocarcinoma patients

Open Access
Research

Hematopoietic stem cells suppress proliferation and enhance differentiation of leukemia cells through regulating apoptotic and inflammatory genes

Research

Contributing and limiting factors to guideline-adherent therapy in senior and elderly breast cancer patients: a questionnaire-based cross-sectional study using clinical and cancer registry data in Germany

Open Access
Research

Role and efficacy of capecitabine in the anthracycline-free regimen in breast cancer patients: a systematic review and meta-analysis

Review

Emerging markers of cancer cachexia and their relationship to sarcopenia

Open Access
Research

Guiding the postoperative radioactive iodine-131 therapy for patients with papillary thyroid carcinoma according to the prognostic risk groups: a SEER-based study

Research

Neu im Fachgebiet Onkologie

ctDNA erkennt minimale Resterkrankung beim Melanom

25.04.2025
Tumormarker
Nachrichten

Die Diagnose einer minimalen Resterkrankung mithilfe zirkulierender Tumor-DNA könnte (ctDNA) auch das Management von Patientinnen und Patienten mit Melanomen im Stadium III bereichern, wie Ergebnisse einer Studie nahelegen – auch wenn die Methode noch nicht perfekt funktioniert.

Höhere Dosis von Dexamethason senkt Überlebenschancen

25.04.2025
Zerebrale Metastasen
Nachrichten

Personen mit Hirnmetastasen, die perioperativ höhere kumulative Dosen von Dexamethason erhalten, haben eine schlechtere Prognose. Um die Ergebnisse zu verbessern, bedarf es strengerer Dosierungsschemata.

Ringen um den richtigen Umgang mit Zufallsbefunden

24.04.2025
DGP 2025
Kongressbericht

Wenn 2026 in Deutschland das Lungenkrebsscreening mittels Low-Dose-Computertomografie (LDCT) eingeführt wird, wird es auch viele Zufallsbefunde ans Licht bringen. Das birgt Chancen und Risiken.

Bald 5% der Krebserkrankungen durch CT verursacht

23.04.2025
Computertomografie
Nachrichten

Die jährlich rund 93 Millionen CTs in den USA könnten künftig zu über 100.000 zusätzlichen Krebserkrankungen führen, geht aus einer Modellrechnung hervor. Damit würde eine von 20 Krebserkrankungen auf die ionisierende Strahlung bei CT-Untersuchungen zurückgehen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Identification of glycogene-based prognostic signature and validation of B3GNT7 as a potential biomarker and therapeutic target in breast cancer